Camber Capital Management LP Avrobio, Inc. Transaction History

Camber Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $2.11 Million - $6.6 Million	-1,633,333 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $5.18 Million - $9.08 Million	-1,500,000 Reduced 47.87%	1,633,333 $6.29 Million
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $17.1 Million - $22.8 Million	1,333,333 Added 74.07%	3,133,333 $43.7 Million
Q3 2020 Nov 16, 2020	BUY	$12.99 - $19.41 $5.85 Million - $8.73 Million	450,000 Added 33.33%	1,800,000 $23.4 Million
Q1 2020 May 15, 2020	BUY	$10.08 - $27.21 $7.56 Million - $20.4 Million	750,000 Added 125.0%	1,350,000 $21 Million
Q4 2019 Feb 14, 2020	BUY	$13.05 - $21.88 $1.31 Million - $2.19 Million	100,000 Added 20.0%	600,000 $12.1 Million
Q3 2019 Nov 14, 2019	BUY	$14.12 - $23.44 $7.06 Million - $11.7 Million	500,000 New	500,000 $7.06 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.